文献速递神经肿瘤

苯达莫司汀用于替莫唑胺难治性复发性间变性胶质瘤的挽救治疗:一项前瞻性II期试验

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.
PubMed 文献 · J Neurooncol · 2017-02-16

这项前瞻性II期试验评估苯达莫司汀在放疗和替莫唑胺难治性复发性间变性胶质瘤成人患者中的疗效与毒性。26例患者接受苯达莫司汀100 mg/m²/天,连续2天,每4周一次。6个月无进展生存率为27%,未达到预设的40%研究成功标准;毒性可控,单药活性有限。

要点

  • 苯达莫司汀在替莫唑胺难治性复发性间变性胶质瘤中6个月无进展生存率为27%,未达预设40%的成功阈值。
  • 3级治疗相关毒性包括淋巴细胞减少(11例,其中3例为4级)等,1例因毒性终止治疗。
  • 中位无进展生存期2.7个月,最佳影像学缓解为部分缓解1例(4%)、疾病稳定13例(50%)。

核心结论

  • 在替莫唑胺难治性复发性间变性胶质瘤患者中,苯达莫司汀毒性可控,单药活性有限,未达到预设研究标准。

研究设计与样本

  • 前瞻性II期试验,纳入26例成人(16例男性,10例女性;中位年龄40岁,范围30-65岁)放疗和替莫唑胺难治性复发性间变性胶质瘤患者,其中12例为第一次复发,17例为第二次复发。

主要发现

  • 既往挽救治疗包括再次切除14例、化疗11例和再放疗2例。
  • 3级治疗相关毒性包括淋巴细胞减少11例(其中3例为4级)、肌痛、肺炎、腹泻、白细胞减少、过敏反应和血小板减少各1例;1例因毒性终止治疗;5次因淋巴细胞减少延迟给药;无因毒性减量。
  • 中位治疗周期数为3(范围1-8)。
  • 最佳影像学缓解:疾病进展12例(46%)、疾病稳定13例(50%)、部分缓解1例(4%)。
  • 中位无进展生存期2.7个月(范围1-52),6个月和12个月无进展生存率分别为27%和8%。

关键数值与推荐

  • 苯达莫司汀一个周期定义为连续2天给药(100 mg/m2/天),每4周一次。
  • 治疗成功定义为6个月无进展生存率≥40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is no standard therapy for recurrent anaplastic glioma (AG). Salvage therapies include alkylator-based chemotherapy, re-resection with or without carmustine implants, re-irradiation and bevacizumab. Bendamustine is a novel bifunctional alkylator with CNS penetration never previously evaluated in AG. Assess response and toxicity of bendamustine in recurrent AG in a phase II trial. Adults with radiation and temozolomide refractory recurrent AG were treated with bendamustine. A cycle of bendamustine was defined as two consecutive days of treatment (100 mg/m2/day) administered once every 4 weeks. Success of treatment was defined as progression free survival (PFS) at 6 months of 40 % or better. Twenty-six adults [16 males; 10 females: median age 40 years (range 30-65)] were treated, 12 at first recurrence and 17 at second recurrence. Prior salvage therapy included re-resection (14), chemotherapy (11) and re-radiation (2). Grade 3 treatment-related toxicities included lymphopenia (11 patients; Grade 4 in 3), myalgia, pneumonia, diarrhea, leukopenia, allergic reaction and thrombocytopenia in one patient each. One patient discontinued therapy due to toxicity. There were five instances of bendamustine dose delays all due to lymphopenia. There were no dose reductions due to toxicity. The median number of cycles of therapy was 3 (range 1-8). Best radiographic response was progressive disease in 12 (46 %), stable disease in 13 (50 %) and partial response in 1 (4 %). Median, 6- and 12-month PFS was 2.7 months (range 1-52), 27 and 8 % respectively. In patients with recurrent AG refractory to Z, bendamustine has manageable toxicity and modest single agent activity though not meeting pre-specified study criteria.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Chamberlain MC, Colman H, Kim BT, et al. Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. J Neurooncol. 2017. PMID: 28204914. doi:10.1007/s11060-016-2241-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。